AGM
CHRS icon

Alpine Global Management’s Coherus Oncology CHRS Stock Holding History

Alpine Global Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,714
Closed -$101K – 204
2022
Q4 		$101K Buy
+12,714
New +$97.8K 0.03% 259

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Alpine Global Management's CHRS Position: Q1 2023 in Review

Alpine Global Management sold out of Coherus Oncology (CHRS) in Q1 2023, closing a stake of 12,714 shares — an estimated $101K sold.

Alpine Global Management first reported a position in CHRS in Q4 2022 and held it in 1 quarter. The position peaked at $101K in Q4 2022. 163 funds tracked by Wall St. Rank hold CHRS as of Q1 2023.

  • Alpine Global Management reported no remaining Coherus Oncology position as of Q1 2023 after selling out during the quarter.
  • Alpine Global Management sold 12,714 Coherus Oncology shares in Q1 2023, an estimated $101K.
  • Alpine Global Management first reported a position in Coherus Oncology in Q4 2022 and held it in 1 quarter.
  • Alpine Global Management's Coherus Oncology position peaked at $101K in Q4 2022.
  • 163 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2023.

Based on Alpine Global Management's 13F filing for Q1 2023, filed 15 May 2023.